Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,676.55
(
-0.59%
)
US TECH 100
24,040.40
(
-0.38%
)
Dow Jones
46,549.03
(
-0.95%
)
Brent Oil
105.63
(
4.94%
)
Bitcoin
71,199.90
(
-3.71%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: pollyvonwog post# 112027

Thursday, 01/06/2011 1:52:45 PM

Thursday, January 06, 2011 1:52:45 PM

Post# of 257253

…why would [MNTA’s] lawsuit cause Marth to admit the application may get something other than approval.

MNTA and NVS believe that the only way Teva could get FDA approval for Lovenox is by stealing or infringing MNTA’s IP. Now that the patent-infringement lawsuit has been served on Teva, the kinds of assertions about Lovenox that we’ve come to expect from Bill Marth could conceivably be used against Teva in court. This has had the effect of gagging Marth’s urge to spout BS in presentations to investors.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now